Redunera – Provisional Patent Summary

Prepared by: Kunfirm Technologies

Filing Type: Provisional Utility Patent

Date: June 30, 2025

# Title of Invention

Redunera: Logic-Gated Renal Therapeutic with Entropy Stabilization and Immune Feedback Modulation

# Technical Field

The present invention relates to therapeutic compositions and methods for treating chronic kidney disease (CKD) in patients with comorbid hypertension or type 2 diabetes. Specifically, the invention integrates logic-driven design principles to create a modular, adaptive drug formulation using entropy buffers, renal targeting, immune logic dampening, and environment-responsive release systems.

# Background

Conventional renal therapeutics often rely on linear pharmacokinetics and systemic delivery, leading to inefficiencies and off-target effects. Redunera addresses this by introducing a logic-based structure for precision delivery and dynamic adaptation to oxidative and inflammatory stress, developed under the Moleculogic Tier 4 system.

# Summary of the Invention

Redunera is a multi-layered composition integrating the following features:  
- An entropy stabilization buffer (taurine or histidine-zinc complex)  
- Renal-targeted delivery vector (e.g., dextran nanoparticle)  
- Logic-modulated immune dampener (curcumin analog or calcitriol)  
- ROS/pH-sensitive polymer for conditional release  
  
This composition is not derived from any existing compound or prior formulation. It is uniquely generated through Kunfirm’s SEI-governed Moleculogic logic blueprint engine.

# Preliminary Claims

1. A logic-governed therapeutic composition comprising:  
 - a redox-stabilizing agent,  
 - a kidney-targeting delivery agent,  
 - a feedback-responsive immune modulator,  
 - and a reactive release system that activates under oxidative stress.

2. The composition of claim 1, wherein said redox-stabilizing agent is taurine or a histidine-zinc complex.  
3. The composition of claim 1, wherein the delivery agent is a renal-targeted ligand or polymer.  
4. The composition of claim 1, wherein the immune modulator is a curcumin analog or calcitriol.  
5. The composition of claim 1, wherein the release system comprises a ROS- or pH-sensitive polymer matrix.